The fluorouracil (5FU) market comprises chemotherapeutic agent used for the treatment of cancer, primarily for colorectal cancer as it suppresses the synthesis of the DNA nucleotide thymidine and RNA synthesis. 5FU has advantages over other chemotherapeutic agents as it exhibits high efficacy against a wide range of cancers including breast, head and neck, gastric, and pancreatic cancer. With rising cases of cancer across the globe, the need for effective chemotherapy drugs has increased considerably.
The global fluorouracil (5FU) market is estimated to be valued at US$ 4.04 Mn in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Fluorouracil (5FU) Market Size are Kurihama Medical and Addiction Center, National Hospital Organization Kurihama Medical and Addiction Center, Osaka National Hospital, National Hospital Organization Nagasaki Medical Center, National Hospital Organization Kochi Medical Center, National Center for Mental Health (Nashilgil Hospital), Seoul St. Mary's Hospital, Samsung Medical Center, Yonsei University Health System, Asan Medical Center, Beijing HuiLongGuan Hospital, Peking University Sixth Hospital, Beijing Huilongguan Hospital, Shanghai Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, National Institute of Mental Health and Neurosciences (NIMHANS), All India Institute of Medical Sciences (AIIMS), Tata Memorial Hospital, VIMHANS (Vidyasagar Institute of Mental Health and Neurosciences), Schizophrenia Research Foundation (SCARF), Promises Healthcare (Singapore), The Cabin Chiang Mai (Thailand), The Dawn Medical Rehab and Wellness (Thailand), The Solace Sabah (Malaysia), The Kusnacht Practice (Singapore).
The key opportunities in the fluorouracil (5FU) market include rising demand for chemotherapy drugs in developing economies and increasing adoption of 5FU biosimilars to reduce the treatment costs. Additionally, growing number of clinical trials evaluating the efficacy of 5FU in combination with other drugs is anticipated to present lucrative opportunities.
Globally, the leading market players are focusing on expansion strategies across Asian and Latin American countries. With rapidly increasing patient population and healthcare spending in China and India, Asia Pacific is estimated to be one of the most lucrative markets. Moreover, supportive regulatory environment and healthcare reforms in Brazil and Mexico are positively impacting the uptake of 5FU in Latin American countries.
Market drivers
The key driver for fluorouracil (5FU) market is the rising prevalence of advanced and metastatic cancers worldwide. According to WHO, cancer is leading cause of death globally, accounting for nearly 10 million deaths in 2020. Colon cancer also known as colorectal cancer is third most common cancer type globally.
Market restrain
The major restrain for fluorouracil (5FU) market is its toxic side effects. Being chemotherapy drug, 5FU has significant side effects including severe diarrhea, mouth sores, low blood cell count, hair loss, nausea, vomiting, etc. Its intensive administration through infusion also causes patient non-compliance. Stringent regulations for approval of oncology drugs also restricts market growth.
Segment Analysis
The Fluorouracil (5FU) market is dominated by the colorectal cancer sub segment. Colorectal cancer accounts for over 50% of the total Fluorouracil market share globally. 5FU is one of the first line treatment drugs used either alone or in combination with other therapies like levamisole for treating colorectal cancer. Since colorectal cancer accounts for majority of the cancer cases globally and 5FU has been the standard treatment for over three decades for colorectal cancer, it dominates the Fluorouracil market.
Global Analysis
Regionally, North America dominates the Fluorouracil market currently accounting for over 30% share. This is due to number of factors like rising cases of colorectal cancer, presence of advanced healthcare infrastructure and availability of advanced treatment options in the region. Asia Pacific is the fastest growing region for Fluorouracil market expanding at a CAGR of around 8%. This high growth can be attributed to growing cases of gastrointestinal cancers coupled with improving access to cancer treatment in countries like China, India and Japan. Rising healthcare spending and increased adoption of newer treatment therapies have been driving Fluorouracil market in Asia Pacific region.
Get more insights on Fluorouracil (5FU) Market
Also Read Related Article on Microfluidic Market
Comments
0 comment